The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Receptor Tyrosine Kinase Coactivation Networks in Cancer
Open accessAbstract
Cancer cells employ multiple mechanisms to evade tightly regulated cellular processes such as proliferation, apoptosis, and senescence. Systems-wide analyses of tumors have recently identified receptor tyrosine kinase (RTK) coactivation as an important mechanism by which cancer cells achieve chemoresistance. This mini-review discusses our current understanding of the complex and dynamic process of RTK coactivation. We highlight how systems biology and computational modeling have been employed to predict integrated signaling outcomes and cancer phenotypes downstream of RTK coactivation. We conclude by providing an outlook on the feasibility of targeting RTK networks to overcome chemoresistance in cancer. Cancer Res; 70(10); 3857–60. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 5×
“A cocktail of EGFR, c-Met, and platelet-derived growth factor receptor (PDGFR) inhibitors resulted in a synergistic decrease in cell viability compared with treatment with any single agent alone (4).”
BackgroundMethodInfluentialNovel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495 · cited 2×
“An example is foretinib, a small molecule inhibitor of Axl, c-Met, and vascular endothelial growth factor receptor (VEGFR), which reduced tumor burden in a mouse model of lung metastasis and overcame lapatinib (an EGFR/ErbB2 inhibitor)-induced resistance in BT474 breast cancer cells (16, 17).”
BackgroundQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350 · cited 2×
“An example is foretinib, a small molecule inhibitor of Axl, c-Met, and vascular endothelial growth factor receptor (VEGFR), which reduced tumor burden in a mouse model of lung metastasis and overcame lapatinib (an EGFR/ErbB2 inhibitor)-induced resistance in BT474 breast cancer cells (16, 17).”
BackgroundSystems-level interactions between insulin–EGF networks amplify mitogenic signaling
Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T., Kaimachnikov, N. P., Timmer, J., Hoek, J. B., & Kholodenko, B. N. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.19 · Cited by 222
Cited by
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Robust network inference using response logic
Gross, T., Wongchenko, M. J., Yan, Y., & Blüthgen, N. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz326 · Cited by 7
Metadata
- Authors
- Xu, A. M., & Huang, P. H.
- Venue
- Cancer Research
- Published
- 2010-05-12
- Volume
- 70
- Issue
- 10
- Pages
- 3857-3860
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2058522541
- Cited by
- 173
- References
- 4
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Receptor Tyrosine Kinase Coactivation Networks in Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-0163
- The paper
- Xu, A. M., & Huang, P. H. (2010). Receptor Tyrosine Kinase Coactivation Networks in Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-0163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.